Oren Livnat, an analyst from H.C. Wainwright, reiterated the Buy rating on Trevi Therapeutics (TRVI – Research Report). The associated price target remains the same with $12.50.
Oren Livnat has given his Buy rating due to a combination of factors surrounding Trevi Therapeutics’ promising developments with their drug Haduvio. The upcoming Phase 2b CORAL study in patients with idiopathic pulmonary fibrosis and chronic cough (IPF-CC) is a significant focus, as it builds on the successful results from previous studies like the CANAL and RIVER trials. These studies demonstrated substantial placebo-subtracted reductions in cough frequency, which de-risks the upcoming trial. The CORAL study is designed to be more comprehensive, involving a larger sample size and more global sites, which increases the reliability of the results.
Additionally, the study’s design is robust, with a parallel-arm approach and multiple dosing regimens, which should provide a clear understanding of the drug’s efficacy. The potential for Haduvio to be the most effective anti-tussive treatment in development is supported by the expected outcomes of the CORAL study, as well as ongoing research in related indications. The positive data from these trials, along with favorable safety profiles and patient-reported outcomes, strengthen Trevi’s position for future FDA negotiations and potential market success. Livnat’s optimism is further reflected in the projected peak sales and the strategic timeline for Haduvio’s market launch, reinforcing the Buy rating for Trevi Therapeutics’ stock.
In another report released yesterday, Leerink Partners also reiterated a Buy rating on the stock with a $11.00 price target.